Stoke Therapeutics reports FY2022 net loss $101.1M; STK-001 shows 55% median seizure reduction

Stoke Therapeutics, Inc.

Net loss for FY2022 was $101.1M ($2.60/share) vs $85.8M ($2.34/share) in 2021; revenue of $12.4M from license agreement.
STK-001 interim analysis: 55% median reduction in convulsive seizure frequency in 6 patients after multiple 45mg doses.
Cash, equivalents, and marketable securities $230.2M at Dec 31, 2022; plus $44.7M raised since, extending runway to end of 2025.
Data from multiple 45mg doses expected mid-2023; 70mg dose data in H2 2023; Phase 3 program planned for 2024.
R&D expenses rose to $77.8M (FY2022) from $54.2M (FY2021) driven by STK-001 and STK-002 development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.